Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer

Caio M. Rocha Lima, Soley Bayraktar, Aurea M. Flores, Jessica MacIntyre, Alberto Montero, Joaquina C. Baranda, John Wallmark, Chia Portera, Rajiv Raja, Howard Stern, Stephanie Royer-Joo, Lukas C. Amler

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

In this multicenter phase Ib study, drozitumab was given in combination with the mFOLFOX6 regimen and bevacizumab in patients with previously untreated, locally advanced recurrent or metastatic colorectal cancer on day 1 of every 14-day cycle. Nine patients were treated at 2 different cohort dose levels of drozitumab. No dose-limiting toxicities occurred at either dose level and the maximum tolerated dose was not reached. Two patients had a partial response of 4.93 and 4.96 months duration. Cohort 2 dose level is the recommended starting dose level for future trials.

Original languageEnglish (US)
Pages (from-to)727-731
Number of pages5
JournalCancer Investigation
Volume30
Issue number10
DOIs
StatePublished - Dec 1 2012

Keywords

  • Apo2 ligand
  • Apoptosis
  • Drozitumab
  • Efficacy
  • Metastatic colorectal cancer
  • Toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Rocha Lima, C. M., Bayraktar, S., Flores, A. M., MacIntyre, J., Montero, A., Baranda, J. C., Wallmark, J., Portera, C., Raja, R., Stern, H., Royer-Joo, S., & Amler, L. C. (2012). Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Cancer Investigation, 30(10), 727-731. https://doi.org/10.3109/07357907.2012.732163